{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:32:21Z","timestamp":1760056341227,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009086","name":"Medical University Sofia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.diagmicrobio.2019.114980","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T11:22:19Z","timestamp":1577704939000},"page":"114980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?"],"prefix":"10.1016","volume":"96","author":[{"given":"Lyudmila","family":"Boyanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumyana","family":"Markovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Gergova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Mitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-0711-9-22","article-title":"Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study","volume":"9","author":"Ben Mansour","year":"2010","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0010","article-title":"Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018","author":"Bluemel","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0015","series-title":"Helicobacter pylori","first-page":"201","article-title":"H. pylori resistance to antibiotics","author":"Boyanova","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/23744235.2015.1082035","article-title":"Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria","volume":"48","author":"Boyanova","year":"2016","journal-title":"Infect Dis (Lond)."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17512433.2019.1654858","article-title":"Multidrug resistance in Helicobacter pylori: current state and future directions","volume":"12","author":"Boyanova","year":"2019","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1523-5378.2012.00935.x","article-title":"Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan","volume":"17","author":"Chang","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0035","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/151543","article-title":"Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori","volume":"2014","author":"Chuah","year":"2014","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/apt.14597","article-title":"Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains","volume":"47","author":"Gatta","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther."},{"issue":"15","key":"10.1016\/j.diagmicrobio.2019.114980_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin","volume":"23","author":"Kocsis","year":"2016","journal-title":"zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV\/Florence consensus report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0060","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/CMR.00033-06","article-title":"Helicobacter pylori detection and antimicrobial susceptibility testing","volume":"20","author":"M\u00e9graud","year":"2007","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0070","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/JCM.02642-10","article-title":"Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium","volume":"49","author":"Miendje Deyi","year":"2011","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114875","article-title":"Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium","volume":"95","author":"Miendje Deyi","year":"2019","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0085","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1523-5378.2011.00912.x","article-title":"Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB","volume":"17","author":"Rimbara","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0095","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2015.02.005","article-title":"Antibiotic resistance of Helicobacter pylori among male United States veterans","volume":"13","author":"Shiota","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160007","article-title":"Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogot\u00e1-Colombia (2009-2014)","volume":"11","author":"Trespalacios-Rang\u00e9l","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.diagmicrobio.2019.114980_bb0115","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3748\/wjg.v21.i9.2786","article-title":"Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319311885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319311885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:53:42Z","timestamp":1760003622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319311885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0732889319311885"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114980","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114980"}}